BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27863448)

  • 1. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
    Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis.
    Wattacheril J; Seeley EH; Angel P; Chen H; Bowen BP; Lanciault C; Caprioli RM; Abumrad N; Flynn CR
    PLoS One; 2013; 8(2):e57165. PubMed ID: 23451176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
    Ochoa-Rios S; O'Connor IP; Kent LN; Clouse JM; Hadjiyannis Y; Koivisto C; Pecot T; Angel PM; Drake RR; Leone G; Mehta AS; Rockey DC
    Mol Cell Proteomics; 2022 May; 21(5):100225. PubMed ID: 35331917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis.
    Tanaka N; Matsubara T; Krausz KW; Patterson AD; Gonzalez FJ
    Hepatology; 2012 Jul; 56(1):118-29. PubMed ID: 22290395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.
    Alamri H; Patterson NH; Yang E; Zoroquiain P; Lazaris A; Chaurand P; Metrakos P
    Anal Bioanal Chem; 2019 Feb; 411(4):885-894. PubMed ID: 30515538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis.
    Lee C; Kim J; Han J; Oh D; Kim M; Jeong H; Kim TJ; Kim SW; Kim JN; Seo YS; Suzuki A; Kim JH; Jung Y
    Nat Commun; 2022 Jan; 13(1):578. PubMed ID: 35102146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
    Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
    Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.
    Gorden DL; Ivanova PT; Myers DS; McIntyre JO; VanSaun MN; Wright JK; Matrisian LM; Brown HA
    PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
    Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
    Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
    Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.